AiViva

Developing treatments that change lives

Print
Claim My Business View on StartEngine
Security Type
Common Stock
Categories
Healthcare/Medical, Technology
Min Investment
$400
Location
Newport Beach, CA
Offering Date
June 17, 2022
Expected Close Date
October 14, 2022
Amount Raised
$650,993
Target Raise
$10K-$5M
No. Investors
171
Security Price
$2
Valuation
$48,800,000
Website
aiviva.com
Number of Employees
9
Cash
$3,601,734
Revenue
$17,000
Short Term Debt
$437,051
Cost of Goods
$0
Long Term Debt
$23,892
Net Income
$-3,960,872

Company Description

AiViva is a clinical stage biotech company which has created proprietary technology and new treatments to address significant, unmet medical needs in ophthalmology, dermatology, urology, and oncology. The company is led by a team of seasoned industry experts who have an outstanding track record in successful drug development, commercialization, and multiple IPOs on the NYSE and NASDAQ.

Perks

StartEngine OWNERS Exclusive Click here to learn more

$400+ Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.

Super Early Bird Bonus
Invest within the first two weeks and receive 15% bonus shares




0
days

11
hours

43
mins

39
secs

$1,000+ Investment
$1,000+ 5% bonus shares

$2,000+ Investment
$2,000+ 5% bonus shares

$5,000+ Investment
$5,000+ 10% bonus shares, plus ability to vote on product names

$10,000+ Investment
$10,000+ 15% bonus shares, Zoom Meeting with Founding Team

$25,000+ Investment
$25,000+ 20% bonus shares, In-person Meeting with Founding Team

Key Deal Facts

AiViva already has successfully raised over $25 million USD, with $4.2 million raised in 2022 alone.
Our diverse product pipeline presents a combined revenue potential of $5.3B. We have four clinical trials (two ongoing, two planned) focused on wet AMD, prostate disorders, and non-melanoma skin cancer.
We have a veteran team with over 300 years of combined experience. AiViva is rated as a top 20 BioPharma company in 2022 by Life Sciences Review.

Security Description

Common stock is a security that represents ownership in a corporation.

Research Reports

No reports have been submitted

Become a Reporter

0 Comments